BMI and Contraceptives Affect New Age-, Sex-, and Puberty-adjusted IGF-I and IGFBP-3 Reference Ranges Across Life Span
Various clinical factors influencing serum levels of insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) are not entirely consistently described. We asked whether body mass index (BMI), contraceptive drugs (CDs), and hormone replacement therapy (HRT) have potential effects on da...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2022-06, Vol.107 (7), p.e2991-e3002 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e3002 |
|---|---|
| container_issue | 7 |
| container_start_page | e2991 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 107 |
| creator | Hörenz, Charlott Vogel, Mandy Wirkner, Kerstin Ceglarek, Uta Thiery, Joachim Pfäffle, Roland Kiess, Wieland Kratzsch, Jürgen |
| description | Various clinical factors influencing serum levels of insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) are not entirely consistently described.
We asked whether body mass index (BMI), contraceptive drugs (CDs), and hormone replacement therapy (HRT) have potential effects on data for interpreting new age-, sex-, and puberty-adjusted reference ranges for IGF-I and IGFBP-3 serum levels.
Subjects were mainly participants from 2 population-based cohort studies: the LIFE Child study of children and adolescents and the LIFE Adult study.
We investigated 9400 serum samples from more than 7000 healthy and 1278 obese subjects between 3 months and 81 years old.
Associations between IGF-I or IGFBP-3, measured with a new electrochemiluminescence immunoassay, and the predictors BMI and CDs were estimated using hierarchical linear modeling.
During infancy, obese children had up to 1 SD score (SDS) higher mean predicted IGF-I values, converging with levels of normal-weight subjects up to 13 years old. Between 20 and 40 years of age, obesity was related to up to -0.5 lower IGF-I SDS values than the predicted values. Obesity had less impact on IGFBP-3. Estrogen- and progestin-based CDs, but not HRT, decreased IGF-I and increased IGFBP-3 (P |
| doi_str_mv | 10.1210/clinem/dgac157 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2640325243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A777587190</galeid><sourcerecordid>A777587190</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-455183c16b8b5d30642ea641ff988021767260e897254d1512e2eb42e076cf323</originalsourceid><addsrcrecordid>eNptkc1rGzEQxUVpaJy01x6DoJceokSfq_XRNo1jcD5IWuhNaLUjs2FX66x20_q_j7Z2cwqCkRh-89C8h9BXRi8YZ_TS1VWA5rLcWMeU_oAmbCoV0WyqP6IJpZyRqea_j9FJjE-UMimV-ISOheIJ4_kEvcxvVtiGEi_a0HfWwbavXiDimffgenwLf_BsA-QcP8LfVEfyfiig63fElk9D7KHEq-UV2Yuk1_yeCPwAHjoIDvCDDZtRznVtjHhdecCPWxs-oyNv6whfDvcp-nX14-fimqzvlqvFbE2cpLwnUimWC8eyIi9UKWgmOdhMMu-neZ6W05nmGYU87ahkyRTjwKFIENWZ84KLU_R9r7vt2ucBYm-aKjqoaxugHaLhmaSCKy5FQr_t0Y2twVTBt6MfI25mWmuVJ1Npoi7eodIpoalcG8BXqf_ewD8HOvBm21WN7XaGUTNGaPYRmkOEaeDs8OWhaKB8w_9nJl4BHXWT3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2640325243</pqid></control><display><type>article</type><title>BMI and Contraceptives Affect New Age-, Sex-, and Puberty-adjusted IGF-I and IGFBP-3 Reference Ranges Across Life Span</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Hörenz, Charlott ; Vogel, Mandy ; Wirkner, Kerstin ; Ceglarek, Uta ; Thiery, Joachim ; Pfäffle, Roland ; Kiess, Wieland ; Kratzsch, Jürgen</creator><creatorcontrib>Hörenz, Charlott ; Vogel, Mandy ; Wirkner, Kerstin ; Ceglarek, Uta ; Thiery, Joachim ; Pfäffle, Roland ; Kiess, Wieland ; Kratzsch, Jürgen</creatorcontrib><description>Various clinical factors influencing serum levels of insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) are not entirely consistently described.
We asked whether body mass index (BMI), contraceptive drugs (CDs), and hormone replacement therapy (HRT) have potential effects on data for interpreting new age-, sex-, and puberty-adjusted reference ranges for IGF-I and IGFBP-3 serum levels.
Subjects were mainly participants from 2 population-based cohort studies: the LIFE Child study of children and adolescents and the LIFE Adult study.
We investigated 9400 serum samples from more than 7000 healthy and 1278 obese subjects between 3 months and 81 years old.
Associations between IGF-I or IGFBP-3, measured with a new electrochemiluminescence immunoassay, and the predictors BMI and CDs were estimated using hierarchical linear modeling.
During infancy, obese children had up to 1 SD score (SDS) higher mean predicted IGF-I values, converging with levels of normal-weight subjects up to 13 years old. Between 20 and 40 years of age, obesity was related to up to -0.5 lower IGF-I SDS values than the predicted values. Obesity had less impact on IGFBP-3. Estrogen- and progestin-based CDs, but not HRT, decreased IGF-I and increased IGFBP-3 (P < 0.01) in adolescents (β IGF-I = -0.45, β IGFBP-3 = 0.94) and adults (β IGF-I = -0.43, β IGFBP-3 = 1.12). Conversely, progestin-based CDs were significantly positive associated with IGF-I (β IGF-I =0.82).
BMI and CDs must be considered when assessing and interpreting the clinical relevance of IGF-I and IGFBP-3 measurements.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/clinem/dgac157</identifier><identifier>PMID: 35294528</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Body mass index ; Children ; Estrogen ; Health aspects ; Hormone therapy ; Obesity in children ; Oral contraceptives ; Pharmaceutical industry ; Protein binding ; Puberty</subject><ispartof>The journal of clinical endocrinology and metabolism, 2022-06, Vol.107 (7), p.e2991-e3002</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><rights>COPYRIGHT 2022 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-455183c16b8b5d30642ea641ff988021767260e897254d1512e2eb42e076cf323</citedby><cites>FETCH-LOGICAL-c402t-455183c16b8b5d30642ea641ff988021767260e897254d1512e2eb42e076cf323</cites><orcidid>0000-0002-4034-5535 ; 0000-0003-2051-1249 ; 0000-0003-2712-1614 ; 0000-0002-2679-5425</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35294528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hörenz, Charlott</creatorcontrib><creatorcontrib>Vogel, Mandy</creatorcontrib><creatorcontrib>Wirkner, Kerstin</creatorcontrib><creatorcontrib>Ceglarek, Uta</creatorcontrib><creatorcontrib>Thiery, Joachim</creatorcontrib><creatorcontrib>Pfäffle, Roland</creatorcontrib><creatorcontrib>Kiess, Wieland</creatorcontrib><creatorcontrib>Kratzsch, Jürgen</creatorcontrib><title>BMI and Contraceptives Affect New Age-, Sex-, and Puberty-adjusted IGF-I and IGFBP-3 Reference Ranges Across Life Span</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Various clinical factors influencing serum levels of insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) are not entirely consistently described.
We asked whether body mass index (BMI), contraceptive drugs (CDs), and hormone replacement therapy (HRT) have potential effects on data for interpreting new age-, sex-, and puberty-adjusted reference ranges for IGF-I and IGFBP-3 serum levels.
Subjects were mainly participants from 2 population-based cohort studies: the LIFE Child study of children and adolescents and the LIFE Adult study.
We investigated 9400 serum samples from more than 7000 healthy and 1278 obese subjects between 3 months and 81 years old.
Associations between IGF-I or IGFBP-3, measured with a new electrochemiluminescence immunoassay, and the predictors BMI and CDs were estimated using hierarchical linear modeling.
During infancy, obese children had up to 1 SD score (SDS) higher mean predicted IGF-I values, converging with levels of normal-weight subjects up to 13 years old. Between 20 and 40 years of age, obesity was related to up to -0.5 lower IGF-I SDS values than the predicted values. Obesity had less impact on IGFBP-3. Estrogen- and progestin-based CDs, but not HRT, decreased IGF-I and increased IGFBP-3 (P < 0.01) in adolescents (β IGF-I = -0.45, β IGFBP-3 = 0.94) and adults (β IGF-I = -0.43, β IGFBP-3 = 1.12). Conversely, progestin-based CDs were significantly positive associated with IGF-I (β IGF-I =0.82).
BMI and CDs must be considered when assessing and interpreting the clinical relevance of IGF-I and IGFBP-3 measurements.</description><subject>Body mass index</subject><subject>Children</subject><subject>Estrogen</subject><subject>Health aspects</subject><subject>Hormone therapy</subject><subject>Obesity in children</subject><subject>Oral contraceptives</subject><subject>Pharmaceutical industry</subject><subject>Protein binding</subject><subject>Puberty</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNptkc1rGzEQxUVpaJy01x6DoJceokSfq_XRNo1jcD5IWuhNaLUjs2FX66x20_q_j7Z2cwqCkRh-89C8h9BXRi8YZ_TS1VWA5rLcWMeU_oAmbCoV0WyqP6IJpZyRqea_j9FJjE-UMimV-ISOheIJ4_kEvcxvVtiGEi_a0HfWwbavXiDimffgenwLf_BsA-QcP8LfVEfyfiig63fElk9D7KHEq-UV2Yuk1_yeCPwAHjoIDvCDDZtRznVtjHhdecCPWxs-oyNv6whfDvcp-nX14-fimqzvlqvFbE2cpLwnUimWC8eyIi9UKWgmOdhMMu-neZ6W05nmGYU87ahkyRTjwKFIENWZ84KLU_R9r7vt2ucBYm-aKjqoaxugHaLhmaSCKy5FQr_t0Y2twVTBt6MfI25mWmuVJ1Npoi7eodIpoalcG8BXqf_ewD8HOvBm21WN7XaGUTNGaPYRmkOEaeDs8OWhaKB8w_9nJl4BHXWT3g</recordid><startdate>20220616</startdate><enddate>20220616</enddate><creator>Hörenz, Charlott</creator><creator>Vogel, Mandy</creator><creator>Wirkner, Kerstin</creator><creator>Ceglarek, Uta</creator><creator>Thiery, Joachim</creator><creator>Pfäffle, Roland</creator><creator>Kiess, Wieland</creator><creator>Kratzsch, Jürgen</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4034-5535</orcidid><orcidid>https://orcid.org/0000-0003-2051-1249</orcidid><orcidid>https://orcid.org/0000-0003-2712-1614</orcidid><orcidid>https://orcid.org/0000-0002-2679-5425</orcidid></search><sort><creationdate>20220616</creationdate><title>BMI and Contraceptives Affect New Age-, Sex-, and Puberty-adjusted IGF-I and IGFBP-3 Reference Ranges Across Life Span</title><author>Hörenz, Charlott ; Vogel, Mandy ; Wirkner, Kerstin ; Ceglarek, Uta ; Thiery, Joachim ; Pfäffle, Roland ; Kiess, Wieland ; Kratzsch, Jürgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-455183c16b8b5d30642ea641ff988021767260e897254d1512e2eb42e076cf323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Body mass index</topic><topic>Children</topic><topic>Estrogen</topic><topic>Health aspects</topic><topic>Hormone therapy</topic><topic>Obesity in children</topic><topic>Oral contraceptives</topic><topic>Pharmaceutical industry</topic><topic>Protein binding</topic><topic>Puberty</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hörenz, Charlott</creatorcontrib><creatorcontrib>Vogel, Mandy</creatorcontrib><creatorcontrib>Wirkner, Kerstin</creatorcontrib><creatorcontrib>Ceglarek, Uta</creatorcontrib><creatorcontrib>Thiery, Joachim</creatorcontrib><creatorcontrib>Pfäffle, Roland</creatorcontrib><creatorcontrib>Kiess, Wieland</creatorcontrib><creatorcontrib>Kratzsch, Jürgen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hörenz, Charlott</au><au>Vogel, Mandy</au><au>Wirkner, Kerstin</au><au>Ceglarek, Uta</au><au>Thiery, Joachim</au><au>Pfäffle, Roland</au><au>Kiess, Wieland</au><au>Kratzsch, Jürgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BMI and Contraceptives Affect New Age-, Sex-, and Puberty-adjusted IGF-I and IGFBP-3 Reference Ranges Across Life Span</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2022-06-16</date><risdate>2022</risdate><volume>107</volume><issue>7</issue><spage>e2991</spage><epage>e3002</epage><pages>e2991-e3002</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Various clinical factors influencing serum levels of insulin-like growth factor I (IGF-I) and its binding protein 3 (IGFBP-3) are not entirely consistently described.
We asked whether body mass index (BMI), contraceptive drugs (CDs), and hormone replacement therapy (HRT) have potential effects on data for interpreting new age-, sex-, and puberty-adjusted reference ranges for IGF-I and IGFBP-3 serum levels.
Subjects were mainly participants from 2 population-based cohort studies: the LIFE Child study of children and adolescents and the LIFE Adult study.
We investigated 9400 serum samples from more than 7000 healthy and 1278 obese subjects between 3 months and 81 years old.
Associations between IGF-I or IGFBP-3, measured with a new electrochemiluminescence immunoassay, and the predictors BMI and CDs were estimated using hierarchical linear modeling.
During infancy, obese children had up to 1 SD score (SDS) higher mean predicted IGF-I values, converging with levels of normal-weight subjects up to 13 years old. Between 20 and 40 years of age, obesity was related to up to -0.5 lower IGF-I SDS values than the predicted values. Obesity had less impact on IGFBP-3. Estrogen- and progestin-based CDs, but not HRT, decreased IGF-I and increased IGFBP-3 (P < 0.01) in adolescents (β IGF-I = -0.45, β IGFBP-3 = 0.94) and adults (β IGF-I = -0.43, β IGFBP-3 = 1.12). Conversely, progestin-based CDs were significantly positive associated with IGF-I (β IGF-I =0.82).
BMI and CDs must be considered when assessing and interpreting the clinical relevance of IGF-I and IGFBP-3 measurements.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>35294528</pmid><doi>10.1210/clinem/dgac157</doi><orcidid>https://orcid.org/0000-0002-4034-5535</orcidid><orcidid>https://orcid.org/0000-0003-2051-1249</orcidid><orcidid>https://orcid.org/0000-0003-2712-1614</orcidid><orcidid>https://orcid.org/0000-0002-2679-5425</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2022-06, Vol.107 (7), p.e2991-e3002 |
| issn | 0021-972X 1945-7197 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2640325243 |
| source | Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Body mass index Children Estrogen Health aspects Hormone therapy Obesity in children Oral contraceptives Pharmaceutical industry Protein binding Puberty |
| title | BMI and Contraceptives Affect New Age-, Sex-, and Puberty-adjusted IGF-I and IGFBP-3 Reference Ranges Across Life Span |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T04%3A10%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BMI%20and%20Contraceptives%20Affect%20New%20Age-,%20Sex-,%20and%20Puberty-adjusted%20IGF-I%20and%20IGFBP-3%20Reference%20Ranges%20Across%20Life%20Span&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=H%C3%B6renz,%20Charlott&rft.date=2022-06-16&rft.volume=107&rft.issue=7&rft.spage=e2991&rft.epage=e3002&rft.pages=e2991-e3002&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/clinem/dgac157&rft_dat=%3Cgale_proqu%3EA777587190%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2640325243&rft_id=info:pmid/35294528&rft_galeid=A777587190&rfr_iscdi=true |